In summary, tumor-specific CD8+ T cells in patients with NSCLC demonstrate divergent differentiation fates toward Temra subset, largely with two distinct phenotypes based on the expression of CD27 and CD28 (CD27−CD28− DN and CD27+CD28+ DP). This evidence concerns the gene CD27 and neoplasm.